Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Trial of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant.

NCT01095003 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.

NCT NCT01095003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01095003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Trial of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant.
Lead sponsor
Pierre Fabre Medicament
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2009
Completion date
October 31, 2015
Enrollment
770 (actual)
Sites
110

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer